ResMed : 39th Annual J.P. Morgan Healthcare Conference

39th Annual J.P. Morgan Healthcare Conference

Mick Farrell - CEO

January 12, 2021

Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

2 © 2021 ResMed | 39th Annual J.P. Morgan Healthcare Conference | January 12, 2021

Company Overview & Strategy

ResMed at a glance

KEY STATISTICS1

LTM 1Q21 REVENUE	$3B
	1989
FOUNDED
LISTED (NYSE, ASX)	1995, RMD
MARKET CAP	~$26B
	San Diego, CA
HEADQUARTERS
EMPLOYEES	~7,500
COUNTRIES SERVED	140+

SLEEP

Revenue by Business

LTM 1Q21

12%
		Devices
51%		Masks & Other
37%		OOH SaaS

OUR BUSINESSES

RESPIRATORY CARE

Revenue by Region

LTM 1Q21

12%			Americas Sleep
			and Respiratory
			Care
	53%		Europe, Asia
35%		and Other

OOH SaaS (U.S. only)

SOFTWARE AS A SERVICE (SaaS)

Delivering a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes

Changing the lives of COPD and other patients with respiratory diseases on their healthcare journey by bringing new solutions for unmet needs

1. network of out-of-hospital healthcare management solutions designed to help providers deliver more personalized care, measurable results and improved health outcomes.

1 As of 30SEP20

4 © 2021 ResMed | 39th Annual J.P. Morgan Healthcare Conference | January 12, 2021